N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=27 IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Phase 1 N=41 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
N/A N=2,384 Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model
Prostate Cancer
Primary: Number of Participants With Clinical Failure After Initiation of Radiotherapy — 315 Participants
Phase 2 N=27 Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms · Neoplasms, Prostate
Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Early Phase 1 N=116 18F-DCFBC PET/CT in Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by…
Phase 2 N=31 Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
Healthy
Primary: Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel. — 2.8; 3.1; 0.6; 0.4 ng/g
Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Phase 2 N=24 Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Prostate Cancer
Primary: Uptake and Retention of Eovist in Prostate Cancers — 2.01; 1.857; 2.52; 2.212 contrast enhancement ratio (CER) — p=0.0008
Phase 2 N=97 Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Prostatic Hyperplasia
Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants
Phase 2 N=44 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Stable Disease at 4 Months. — 2; 5 participants